Economic Evaluation of Treatment of Macular Edema Due to Central or Hemiretinal Vein Occlusion in the SCORE 2 Trial
05/2021
Conference Paper
Authors:
Kymes, S.;
Oden, N.;
VanVeldhuisen, P.C.;
Scott, I.U.
Secondary:
Association for Research in Vision and Ophthalmology Annual Meeting
Location: Denver, Colorado
Keywords:
POSTER PRESENTATION; SCORE2
Abstract:
SCORE2 demonstrated that, for visual acuity letter score (VALS) change, bevacizumab is non-inferior to aflibercept for treatment of macular edema due to central (CRVO) or hemi-retinal vein occlusion (HRVO).
While bevacizumab was non-inferior, aflibercept had a numerical advantage in VALS letters gained.
The average cost for aflibercept is 10 times that of bevacizumab, but it is not known whether the increased VALS gained offsets this cost.
